Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Laurie H. Glimcher, MD


No Ratings Available - Why Not? Make an Appointment

Laurie H. Glimcher, MD

Physician

  • President and CEO, Dana-Farber Cancer Institute
  • Principal Investigator, Cancer Immunology and Virology, Dana-Farber Cancer Institute
  • Richard and Susan Smith Professor of Medicine, Harvard Medical School

Contact Information

  • Office Phone Number617-632-4266
  • Fax617-632-2161

Bio

Laurie H. Glimcher, MD, is the President and CEO of the Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center, and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research.

Dr. Glimcher is a Member of the National Academy of Sciences, the National Academy of Medicine, and the American Philosophical Society; Fellow of the American Academy of Arts and Science; and the former President of the American Association of Immunologists. She is a member of the Cancer Research Institute, Prix Galien, Parker Institute for Cancer Immunotherapy, Repare Therapeutics, Abpro Therapeutics, Biosciences, Inc. Scientific Advisory Boards, the Lasker Award Jury, American Association for Cancer Research, the Association of American Cancer Institutes, and the American Society of Clinical Oncology, and served on the Vice President's Blue Ribbon panel. She previously served on the Board of Directors of Bristol-Myers Squibb Pharmaceutical Corporation, the Waters Corporation, and GSK plc. She currently serves as a consultant for the JPM Healthcare Advisory Committee and is on the Board of Directors of Analog Devices, Inc.

Dr. Glimcher's research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious, and malignant diseases. Dr. Glimcher speaks nationally and internationally on cancer, immunology, and translational medicine and has contributed more than 350 scholarly articles and papers to the medical literature.

Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first female to be appointed as Dean of Weill Cornell Medicine in New York, and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute.

Dr. Glimcher is the recipient of many awards and honors. In 2022, she was named to Modern Healthcare's 50 Most Influential Clinical Executives. In 2018, she received the American Association of Immunologists Lifetime Achievement Award; the Indiana University School of Medicine's Steven C. Beering Award for outstanding research contributions to the advancement of biomedical or clinical science; and the L'Oréal-UNESCO Award for Women in Science. She has also received the 2017 George M. Kober Medal and the 2017 Award for Distinguished Research in the Biomedical Sciences from the Association of Medical Colleges (AAMC).

Dr. Glimcher is a magna cum laude graduate of Radcliffe College and holds an MD degree cum laude from Harvard Medical School. 

Board Certification:

  • Internal Medicine
  • Rheumatology

Fellowship:

  • Harvard Medical School
  • National Institutes of Health, Institute of Allergy and Infectious Diseases

Residency:

  • Massachusetts General Hospital

Medical School:

  • Harvard Medical School

Recent Awards:

  • AAMC, Award for Distinguished Research in the Biomedical Sciences 2017
  • Marion Spencer Fay Award 2017
  • Kober Medal Award from American Association of Physicians 2017
  • Steven C. Beering Award 2015
  • L'Oreal: UNESCO Award 2014
  • Margaret Kripke Legend Award 2014
  • Vanderbilt Prize 2013

Research

About Glimcher Lab

The research interests of the Glimcher lab focus on the molecular pathways that regulate CD4 T helper cell development and activation. The complex regulatory pathways governing T helper cell responses are critical both for the development of protective immunity and for the pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases.

Dr. Glimcher's laboratory has studied the transcriptional pathways that control this important immune checkpoint, leading to many discoveries, including the T-bet and XBP-1 transcription factors, which regulate a variety of immune functions.

Recently, Dr. Glimcher’s laboratory has identified new proteins that control osteoblast and osteoclast commitment and activation in skeletal biology, with significant implications for diseases of bone, including osteoporosis, osteoarthritis, and cancer metastasis to bone. Current studies focus on the ties between the ER stress system and immune function as well as cancer immunity.

 

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Top